AVEO AVEO Pharmaceuticals, Inc.

+0  (1%)
Previous Close 0.58
Open 0.60
Price To book 0.00
Market Cap 44.76M
Shares 75,862,000
Volume 463,046
Short Ratio 3.84
Av. Daily Volume 487,500

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 initiation of dosing announced March 22, 2017. Phase 1 part of trial data due 1H 2017.
Tivozanib + Opdivo
Renal cell cancer (RCC)
Announced September 12, 2016 that its Phase 2 trial has been discontinued
EGFR-mutated Non-small cell lung cancer (NSCLC)
Phase 3 enrollment to be completed June 2017. Futility analysis due mid-2017. Top-line data due 1Q 2018 (Poster session at ASCO June 4, 2017). Abstract TPS4600.
TIVO-3 - tivozanib
Third line treatment of patients with renal cell cancer

Latest News

  1. AVEO Announces Presentations at the 2017 ASCO Annual Meeting
  2. AVEO Announces Submission of Response to Tivozanib Marketing Authorization Application Day 180 List of Outstanding Issues
  3. AVEO Announces Milestone Payment from CANbridge for AV-203
  4. AVEO Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
  5. GGP, CenturyLink Drop into Tuesday’s 52-Week Low Club
  6. AVEO Announces Pricing of $15.0 Million Public Offering of Common Stock
  7. AVEO Announces Proposed Offering of Common Stock
  8. AVEO (AVEO) Reports Narrower-than-Expected Loss in Q4
  9. AVEO reports 4Q loss
  10. AVEO Reports Full Year 2016 Financial Results and Provides Business Update
  11. AVEO Announces First Patient Dosed in Phase 1/2 TiNivo Trial of Tivozanib and Opdivo® (nivolumab) in Advanced RCC
  12. AVEO Pharmaceuticals (AVEO) Q4 Earnings: What's in Store?
  13. Aveo Cancer Drug Tivozanib Clears Safety Review
  14. AVEO Announces TIVO-3 Passes The First Safety Monitoring Committee Safety Review
  15. AVEO Announces Clinical and Regulatory Updates for Tivozanib
  16. AVEO to Present at the 19th Annual BIO CEO & Investor Conference
  17. ETFs with exposure to AVEO Pharmaceuticals, Inc. : December 22, 2016
  18. How AVEO Pharmaceuticals, Inc. (AVEO) Stacks Up Against Its Peers?
  19. AVEO Partner Submits Response to Questions on Tivozanib